Cutaneous alternariosis in a renal transplant recipient: A case report and literature review  by Hsu, Chia-Chi et al.
Asian Journal of Surgery (2015) 38, 47e57Available online at www.sciencedirect.com
journal homepage: www.e-asianjournalsurgery.comCASE REPORT
Cutaneous alternariosis in a renal
transplant recipient: A case report
and literature reviewChia-Chi Hsu a, Shen-Shin Chang b, Po-Chang Lee b,
Sheau-Chiou Chao a,*aDepartment of Dermatology, National Chung Kung University Hospital, College of Medicine,
National Cheng Kung University, Tainan, Taiwan
bDepartment of Surgery, National Chung Kung University Hospital, College of Medicine,
National Cheng Kung University, Tainan, Taiwan
Received 20 December 2011; received in revised form 4 June 2012; accepted 28 August 2012
Available online 18 October 2012KEYWORDS
cutaneous
alternariosis;
organ transplant
recipient;
phaeohyphomycosis* Corresponding author. Department
University, 138 Sheng-Li Road, Tainan
E-mail address: joly@mail.ncku.ed
1015-9584/$36 Copyright ª 2012, Asia
http://dx.doi.org/10.1016/j.asjsur.20Summary Organ transplant recipients under immunosuppressive therapy have a highly
increased risk of acquiring unusual opportunistic infections. Diagnosis of the etiology of infec-
tion may be difficult in clinical manifestations, which need further histological and biological
investigations. We recently treated a male renal transplant recipient with a cutaneous phaeo-
hyphomycosis due to Alternaria species. The diagnosis was based on microscopy and culture of
the skin lesions. Treatment with oral itraconazole for 5 weeks was ineffective, then clinical
improvement was achieved by combination of amphotericin B wet-packing and systemic anti-
fungal therapy with oral voriconazole. Alternaria species are ubiquitous plant-inhabiting sap-
robes, which are increasingly associated with opportunistic phaeohyphomycosis in
immunocompromised individuals. To the best of our knowledge, this is the second case report
noting sporotrichoid pattern as the manifestation of cutaneous alternariosis. In this context,
we reviewed recent renal-transplant-related cutaneous alternariosis reported in the English-
language literature during 1995 to 2011 to summarize its clinical features and outcomes,
and to guide clinicians in the care of kidney transplant patients with cutaneous alternariosis.
Copyright ª 2012, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.of Dermatology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung
, Taiwan.
u.tw (S.-C. Chao).
n Surgical Association. Published by Elsevier Taiwan LLC. All rights reserved.
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Survival following organ transplantation has significantly
improved during the past decade. One of the reasons is that
rejection rates have dramatically declined due to the
development of immunosuppressants. However, organ
transplant recipients under immunosuppressive therapy
have a highly increased risk of acquiring unusual opportu-
nistic infections such as phaeohyphomycosis.1 Phaeohy-
phomycosis is a heterogeneous group of diseases caused by
hyphomycetous fungi that develop in host tissue in the form
of dark-walled melanized septate mycelial elements, which
are ubiquitous in nature, but rarely cause human disease.2,3
The majority of cases of phaeohyphomycosis due to Alter-
naria species have been encountered in immunocompro-
mised individuals,4,5 and some authors have suggested that
it may be an emerging opportunistic infection in transplant
recipients.1
2. Case report
A 61-year-old male retired laborer had been transplanted
with a cadaver kidney because of end-stage renal disease
secondary to diabetic nephropathy. There was acute
rejection 3 months after transplantation, and the patient
was taking the following long-term immunosuppressive
drugs: tacrolimus (1 mg twice a day orally), mycophenolate
mofetil (500 mg triple a day orally), and methylpredniso-
lone (8 mg once a day orally). After the episode of acute
rejection, the serum creatinine level was relative stable,
around 1.0e1.5 mg/dL. One year after transplantation, heFigure 1 (A) One crusted verrucous plaque on the external aspec
with ulceration over the left lower extremity in a sporotrichoid padeveloped a verrucous plaque on the left lateral ankle. The
patient did not recall any local trauma occurring since
transplantation. Three months later, he underwent excision
of the verruca with microabscess. The pathological finding
was pseudoepitheliomatous hyperplasia with hyperkera-
tosis and foci of neutrophilic aggregates, compatible with
verruca with inflammation. No special staining for micro-
organisms was carried out. Two months after surgery,
multiple newly formed tender nodules and ulcers on the
left lower extremity were noted. There was no fever,
cough, or manifestations of systemic illness. On examina-
tion, a well-defined, 9-cm diameter, dark-red erythema-
tous plaque with rice-grain-sized black papules and crusts
were present on the lateral aspect of the left ankle
(Fig. 1A). Multiple sporotrichoid erythematous to viola-
ceous nodules and ulcers on the left lower extremity were
also found (Fig. 1B and C). To evaluate this process further,
an incisional biopsy was performed on the left thigh, which
showed marked neutrophilic infiltrates primarily in the
reticular dermis and dermosubcutaneous junction, without
caseous necrosis or microabscess formation (Fig. 2A). No
bacteria were identified by Gram’s stain. Grocott’s
Methenamine Silver and periodic acid-Schiff stain demon-
strated a few spores within the infiltrate in the reticular
dermis (Fig. 2B). The diagnosis was suppurative dermatitis
with deep fungal infection. Culture of the biopsy specimen
yielded Alternaria species (Fig. 2C). To exclude the possi-
bility of a systemic infection, chest X-ray was performed,
with negative results. The final diagnosis was cutaneous
alternariosis.
The size and number of the lesions made local excision
technically difficult, thus, the patient was started ont of the right ankle; (B and C) skin lesions were multiple nodules
ttern.
Alternariosis in renal transplant recipient 49itraconazole orally at a dose of 400 mg daily. Despite
treatment for 5 weeks, the lesions progressed to deeper
ulcers with enlarging perimeter and more pain. Itracona-
zole therapy was discontinued, and treatment was
commenced with oral voriconazole (400 mg per day) with
daily topical wet-packing with amphotericin B (1 mg/mL,
total 10 mg) for 11 days was, in association with close
follow-up of tacrolimus serum levels. The serum trough
level of tacrolimus was around 10 ng/mL before vor-
iconazole use and was elevated to 29 ng/mL on day 4 of
voriconazole therapy. The tacrolimus dose was adjusted
from 2 mg to 1 mg daily to maintain the therapeutic level.
Renal function remained stable after the adjustment.
Dramatic improvement was noted a few days later and the
patient received regular treatment and follow-up at ourFigure 2 (A) There were marked neutrophilic infiltrates prima
without caseous necrosis or microabscess formation (hematoxylin
spores within the infiltrate in the reticular dermis (400). (C) Mac
grey fungal colonies with wooly texture grown in Sabouraud’s dextoutpatient department. Two months after treatment with
voriconazole, we observed almost-resolved lesions with
residual scars (Fig. 3). Unfortunately, during the third
month of voriconazole treatment, the patient was admitted
because of pneumonia and the serum trough level of
tacrolimus was 36 ng/mL. Eventually, the patient died from
bacterial sepsis with multiorgan failure. At the time of
death, the patient had residual scars without active lesions
on his left leg.3. Literature review and discussion
Alternaria has worldwide distribution and is a large and
complex genus that encompasses hundreds of species, butrily in the reticular dermis and dermosubcutaneous junction
and eosin, 100). (B) Periodic acid-Schiff stain showed a few
roscopic appearance of cultured Alternaria Spp.: typical dark-
rose agar.
Figure 3 Near resolution of ulcers had occurred after 8 weeks of treatment with voriconazole.
50 C.-C. Hsu et al.only eight have been involved in human or animal infec-
tions,6 with many species being common saprophytes in soil
and air. It can cause several different types of human
infections, such as paranasal sinusitis, ocular infections,
cutaneous and subcutaneous infections, and, more rarely,
granulomatous pulmonary disease, and disseminated
disease.7 However, skin is the most frequent site of infec-
tion with around 200 cases of cutaneous alternariosis being
reported to date.7 Although Alternaria infects mainly
immunocompromised hosts, infections in immunocompe-
tent hosts have also been reported.5 The incidence of
cutaneous alternariosis in transplant recipients is 1 in 1000
in the United States.8 Including the present patient,
a totality of 34 kidney transplant patients with cutaneous
alternariosis have been reported in the English-language
literature since 19958e30: 25 men and nine women, aged
36e73 years (mean: 55 years). Most of the patients were
following different immunosuppressive treatment regimens
after transplantation (Table 1). The incubation gap (from
the date of last transplant to lesion formation) was uneven,
with a range of 2 months to 8 years. Most of the lesions
(73%) happened within 1 year after the date of final
transplantation. This might have been due to the relatively
high dose of immunosuppressants during the first year after
transplantation. The mean duration from rash formation to
diagnosis of Alternaria infection was 3.7 months. In the
present case, the solitary verrucous lesion on the left
lateral ankle was diagnosed as verruca with inflammation
initially, and progressed to multiple sporotrichoid nodules
and ulcers 2 months later. Delayed diagnosis made local
excision technically difficult because of the presentation of
multiple lesions. Therefore, diagnosis of uncharacteristic
inflammatory skin lesions in transplant recipients must
include an appropriate search for infection, especially
fungi. Further special stains or fungal culture could giveclues to fungal infection. Sites of cutaneous alternariosis
are summarized in Table 2. All lesions were located on
exposed areas, except for one on the buttock. Most of the
cases had no trauma history with only five (14.7%) cases
having a local trauma history. Only one patient (Case 9)
might have had systemic involvement. This patient pre-
sented with newly formed pulmonary infiltrate as well as
microscopically confirmed lesions on three noncontiguous
body sites, which strongly suggests that the disease was
disseminated, although fungi could not be detected in the
bronchoalveolar lavage fluid samples. This tendency for
Alternaria infections to remain locally invasive without
dissemination may be related to its active growth in vitro at
20 C, with inhibited growth at 37 C.31 The spectrum of
clinical presentations is broad. The case presented here
appeared remarkable for the sporotrichoid distribution in
the skin lesions. Such a distribution is mainly seen in
sporotrichosis caused by Sporothrix schenckii, but has also
been described in mycobacterial infections and leishmani-
asis. To the best of our knowledge, the clinical picture was
first documented with cutaneous alternariosis in 200132 and
this is only the second report since then.
Alternaria can be isolated from normal human skin or as
a laboratory contaminant, therefore, its involvement in
human infection must be verified by histological evidence
of its presence in tissue. All 34 cases had received skin
biopsy and 23 of them were described in the text, which are
reviewed here. Fungal elements were detected in each of
the biopsy specimens, thus leading toward the diagnosis of
deep fungal infection. For further identification, mycolog-
ical culture is required. All 34 fungal cultures form biopsy
specimens yielded Alternaria species, except one that
remained negative, from a patient who was diagnosed by
real-time polymerase chain reaction. Half of them were
identified to species level. Alternaria alternata, Alternaria
Table 1 Characteristics of 34 patients with dermal cuta-
neous alternariosis, as identified in a literature review.
Characteristic No. of patients
Sex
Male 25
Female 9
Under immunosuppressive
treatment, n Z 33
32
Incubation gap (mo),a n Z 26
0e6 9
7e12 10
13e24 3
>24 4
Duration of diagnosis(mo),b n Z 26
0 3
1e3 13
4e6 7
>6 3
History of trauma, n Z 34 5
Systemic involvement 1
Pathogen, n Z 34
NI 17
Alternaria alternata 11
Alternaria tenuissima 3
Alternaria infectoria 2
Alternaria chartarum 1
Prognosis, n Z 34
Eventually cured 26
Died of diseasec 1
DOD 4
Lost to follow-up 3
Initial treatment of choice
(cured/no. of cases), n Z 31
Antifungal drug 3/19
Operation 1/3
Combination therapy 5/6
Topical therapy 3/3
Eventually cured by, n Z 26
Operation 1
Antifungal drug 6
Combination therapy 16
Topical therapy 3
Relapse during follow-up, n Z 20 2
DOD Z died of other disease; NI Z not identified to species
level.
a From last transplant to date of lesion formation.
b From rash formation to diagnosis of Alternaria infection.
c No autopsy.
Table 2 Sites of dermal cutaneous alternariosis in 34
patients.
Lesion no. No. of patients
Solitary 21
Multiple 13
Multifocal (>2 sites) 9
Body site
Face 1
Trunk 1a
Upper extremities 7
Lower extremities 29
Number of patients was more than 34, because each location of
a lesion was included if multiple body sites were affected.
a Buttock.
Alternariosis in renal transplant recipient 51tenuissima and Alternaria infectoria were the species most
often implicated.
The course of cutaneous alternariosis in this group was
very capricious and treatment was not definitively stan-
dardized. The treatments and outcomes of the reported
cases are summarized in Table 3.4,8e30 Three cases were
lost to follow-up during the treatment and excluded from
the therapeutic analysis. Successful treatment rate was
83.8%. Most of the cases (61.5%) were cured by combination
therapy with surgery and systemic antifungal drugs. Sixcases (23%) were cured by systemic antifungal drugs alone.
In four (15.3%) cases, infection was resolved by local
treatment such as thermotherapy, excisional surgery, and
daily occlusive application of ketoconazole. Only one
patient (Case 25) might have died from Alternaria infection
but no autopsy was performed. Four cases (12.9%),
including the present case, died of other disease during
treatment, between 7 days and 12 years (time of diag-
nosis). The most recalcitrant case, Case 30, underwent
excision combined with several antifungal drugs such as
itraconazole, voriconazole and caspofungin during the 12-
year treatment and eventually died of post-transplant
lymphoproliferative disorder. Despite the relatively high
cure rate (83.8%), most of the therapeutic plans had been
changed during the treatment course. Surgical intervention
was used as an adjunct to oral therapy for some patients.
Systemic antifungal medication had to be replaced by
others for various reasons (e.g., poor response and adverse
drug reaction).
Twenty cases were followed up for 6 months to 6 years
(mean: 23 months). Relapse occurred in two cases (10%)
after 1.5 and 2 years. In our case the infection was
refractory to itraconazole. Voriconazole proved an effec-
tive alternative, resulting in disappearance of the lesions.
The patient’s death did not permit proper follow-up of the
cutaneous lesions, so we cannot know if there would have
been a relapse after drug withdrawal.
In summary, diagnosis of uncharacteristic inflammatory
skin lesions in transplant recipients must include an
appropriate search for infection, especially fungi. Further
special stains or fungal culture could give clues to fungal
infection. In the present case, the solitary verrucous lesion
on the left lateral ankle was diagnosed as verruca with
inflammation initially, and progressed to multiple sporo-
trichoid nodules and ulcers 2 months later. Delayed diag-
nosis made combination therapy technically difficult
because of the presentation of multiple lesions. According
to the reviewed cases, we suggest that excisional surgery,
when possible, combined with systemic antifungal therapy
are the choice of treatment in kidney transplant recipients
with cutaneous alternariosis. Within the systemic anti-
fungal regimens, itraconazole is generally most effective
for treatment of alternariosis. Besides close monitoring of
adverse effects, drug serum level and adjusting the dosage
Table 3 Cutaneous alternariosis in renal transplant recipients.
Case
no.
Age/
Sex
Immune
suppression
Incubation
gap (mo)
Duration
(mo)
Lesion/location Systemic
involvement
Trauma
Hx
Pathology/
presence
of fungal elements
(special stain)
Culture Course and
treatment
Duration of
follow-up,
outcome
Ref.
1 61/M Tac, MMF,
steroid
12 5 Nodules, ulcers/
Left lower
extremity
N N Neutrophilic
infiltrate/Y (PAS,
GMS)
NI Itra 200 mg for 5
wk/ progression,
change to Vori
400 mg for 3
mo þ amphB wet
packing for 11 d,
almost healed
DOD
2 50/F CsA, AZA,
steroid
12 2 One nodule/ Left
leg
N Y Granulomatous
inflammatory/ Y
(PAS)
NI. Daily occlusive
local application of
Keto for 2
mo/ resolved
18 mo f/u:
no lesion
9
3 55/M CsA, steroid ND 4 Two nodules/
right leg
N Y Hyperplasic
epidermis, giant-
cell epithelioid
granulomas with
microabscess/ Y
(H&E, FMS, GMS)
A. tenuissima Ex/ recurrence 1
mo later,
Ex/ recurrence 2
mo later, Ex þ Itra
100 mg for 2
mo/ resolved
12 mo f/u:
no lesion
10
4 70/M CsA, AZA,
steroid
2 4 Ulcers/ right leg,
nodules/ right
arm
N N Pseudoepi-
theliomatous
hyperplasia with
dermal abscess/Y
(H&E, GMS)
A. alternata Itra 400 mg for 2.5
mo/ resolved
ND 11
5 58/ F CsA, AZA,
steroid
39 6 Nodules/right
leg
N N Pseudoepi-
theliomatous
hyperplasia,
granulomatous
infiltrate/Y (H&E,
PAS)
A. tenuissima Terb 250 mg for 2
mo þ
electrosurgical
destruction/
resolved
9 mo f/u:
no
lesion
12
6 52/ F CsA, steroid 60 ND One plaque/
right hand
N N Granulomatous
inflammatory/Y
(PAS, GMS)
NI Itra 100 mg for 1
mo/ no effect
DOD 13
7 63/ F CsA, AZA,
steroid
11 1 Nodules/nasal
septum, left leg,
right knee
N N Granulomatous
inflammatory/Y
(PAS)
A. chartarum Itra 200 mg for 3
mo þ decreased
AZA and DC
steroid/
resolved
12 mo f/u:
no lesion
14
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8 44/M ND 4 2 One nodule/ left
foot
N N ND/ND NI Itra 400 mg for 2
mo/ no response,
Ex þ amphB for 1.5
mo/ resolved
ND 15
9 60/M Tac, steroid 5 0 Nodules/ right
thumb, feet
Y (lung) N Dermal
microabscess,
giant cells/Y
(H&E, FMS)
NI Itra 400 mg for 0.73
mo þ serial
Ex/ progression,
liposomal amph B
for 1
mo/ resolved
20 mo f/u:
no lesion
16
10 68/ F Tac, steroid 8 2 One nodule/
right knee
N N Granuloma/Y
(PAS, GMS)
A. alternata Ex þ Itra 200 mg
for 1
mo/ resolved
10 mo f/u:
no lesion
17
11 58/M CsA, AZA,
steroid
48 0 Multiple
papules/both
forearms
N N Microabscess,
granuloma/Y
(H&E, GMS)
NI Itra 200 mg for 6
mo/ progress,
400 mg for 4
mo/ new lesions
on left leg,
liposomal amphB
750 mg for 1.5
mo/ resolved
36 mo f/u:
no lesion
18
12 55/M Tac, MMF,
steroid
4 0 Nodules/both
legs
N N Granulomatous
inflammation/Y
(H&E, PAS, GMS)
NI Ex/ resolved 5 mo f/u:
no
lesion
19
13 65/M Tac, MMF 4 4 Ulcers, nodules/
both legs
N N Granulomatous
inflammation/Y
(H&E)
A. alternata Terb 200 mg for 1
mo/ no response,
Itra 200 mg for 6
mo, resolved
ND 20
14 54/ F Tac, MMF 8 ND Two nodules/leg N N ND/Y (H&E) A. alternata Ex þ Itra for
unknown
period/ resolved
20 mo f/u:
no lesion
20
15 58/M CsA, AZA,
steroid
5 0.75 One nodule/ left
thigh
N Y Granuloma Y
(GMS)
NI Ex þ Itra 400 mg
for 3
mo/ resolved
84 mo f/u:
no lesion
21
16 41/M Tac, AZA,
steroid
5 1 One nodule/ left
knee
N Y Granulomatous
inflammation with
intradermal
microabscess/
Y(H&E, GMS)
A. alternata Itra 400 mg for 3
mo/ relapse on
left knee 15 mo
later, Itra 400 mg
for 6 mo þ Ex in
the 5th
mo/ resolved
60 mo f/u:
no lesion
21
(continued on next page)
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Table 3 (continued)
Case
no.
Age/
Sex
Immune
suppression
Incubation
gap (mo)
Duration
(mo)
Lesion/location Systemic
involvement
Trauma
Hx
Pathology/
presence
of fungal elements
(special stain)
Culture Course and
treatment
Duration of
follow-up,
outcome
Ref.
17 65/M AZA, steroid ND 1 One ulcer/left
leg
N N ND/ND NI Liposomal AmphB
3 mg/kg/d for 7
d/ persistent
DOD 4
18 67/M CsA, AZA,
steroid
ND 18 One plaque/
right thigh
N Y ND/ND NI Fluc 100 mg for 7
mo þ Fluc
intralesional
injection/
improvement
Loss f/u 4
19 53/M Nil ND 1 One plaque/ left
buttock
N N ND/ND NI Itra 200 mg 3
mo/ loss f/u
Loss f/u 4
20 55/M MMF, Tac,
steroid
ND 4 One plaque/
right knee
N N ND/ND A. alternata Thermotherapy
/ resolved
12 mo f/u:
no lesion
4
21 55/M MMF, Tac,
steroid
2 4 One plaque/
right knee
N N Chronic and acute
inflammatory
infiltrate/Y (GMS)
A. alternata Thermotherapy for
12 mo/ resolved
24 mo f/u:
no lesion
22
22 28/M Tac, AZA,
steroid
6.5 0.5 One nodule/
right knee
N N florid granuloma/
Y (GMS)
A. tenuissima Itra 400 mg for 0.5
mo, Itra 200 mg for
1 mo þ Ex on the
1st
month/ resolved
36 mo f/u:
no lesion
23
23 52/M CsA, steroid ND ND One nodule/
right forearm
N N Granulomatous
inflammation/
Y(PAS, GMS)
A. alternata Itra 100 mg for 1
mo/
improvement
Loss f/u 24
24 58/M Tac, MMF,
steroid
12 3 Nodules/both
legs
N N Hyperkeratosis,
pseudoepi-
theliomatous
hyperplasia,
microabscess,
granulomatous
infiltrate/ Y (H&E,
PAS, GMS)
NI Itra 400 mg for 1
mo/ change to
cryotherapy due to
nephrotoxic effect
of Tac
interaction/
relapse on right
arm/ Terb 250 mg
for 3 mo/ new
lesion, change to
Flu 100 mg for 4
mo/ resolved
/ relapse on right
leg 24 mo late,
excision/
resolved
24 mo f/u:
no lesion
25
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25 61/M CsA, Pred 96 2 One plaque/
right knee
N N Dermal abscess/Y
(H&E)
A. alternata liposomal amphB
for 0.75
mo/ change to
Itra 400 mg for 10
d/ DC due to
hepatotoxicity/
2 mo later, patient
died of unknown
reason with
pyodermatitis on
right limb s/p
liposomal AmphB
for 0.75 mo
Died of
disease
(no
autopsy)
26
26 47/ F Tac, steroid ND 3 One nodule/ left
ankle
N N Hyperplasic
epidermis with a
granulomatous
reaction/Y (H&E)
A. alternata Vori 150 mg for 10
d/ toxicity of
Tac, change to Itra
400 mg for 5
mo/ resolved
ND 27
27 68/M Tac, MMF,
steroid
ND 2.5 One nodule/
right foot
N N Granulomatous
inflammation/Y
(PAS)
A. infectoria Itra 400 mg for 1
wk, 200 mg for 3
wk, 100 mg for 1
mo/ resolved
ND 28
28 36/M MMF, Tac,
steroid
24 ND Papules/left leg,
left forearm
N N ND/ND NI Itra for 4 mo/ no
improvement,
Ex þ Itra for 4
mo/ resolved
72 mo f/u:
no lesion
8
29 41/M MMF, Tac,
steroid
12 ND One nodule/ left
leg,
N N ND/ND NI Ex/ recurrence
with multiple
lesions on left leg,
Ex þ Itra for 24
mo/ resolved
72 mo f/u:
no lesion
8
30 51/M MMF, Tac,
steroid
7 ND Nodules/both
lower
extremities
N N ND/ND NI Itra for 4 mo/ no
improvement,
Ex þ Itra/ new
lesions on upper
extremities, trunk
and ear/ change
to vori, DC due to
photosensitivity/
Itra: adequate dose
for 4 y, progression
4 y later/ added
caspofungin for 2
mo, keep Itra for 48
mo/ persistent
infection
DOD 8
(continued on next page)
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Table 3 (continued)
Case
no.
Age/
Sex
Immune
suppression
Incubation
gap (mo)
Duration
(mo)
Lesion/location Systemic
involvement
Trauma
Hx
Pathology/
presence
of fungal elements
(special stain)
Culture Course and
treatment
Duration of
follow-up,
outcome
Ref.
31 40/M MMF, Tac,
steroid
22 9 One nodule/
right leg
N N ND/ND NI Ex þ Itra for 3
mo/ resolved
48 mo f/u:
no lesion
8
32 60/ F MMF, Tac,
steroid
10 ND One plaque/
right foot
N N ND/ND NI Nodule while
receiving
prophylactic Itra,
excisional þ Vori
for 5 d, DC due to
hepatotoxicity, Itra
for 4.5
mo/ resolved
36 mo f/u:
no lesion
8
33 73/M Tac, MMF,
steroid
24 12 One plaque/
right hand
N N Granuloma,
necrosis/Y (PAS)
Culture (e),
RT-PCR:A.
infectoria
Itra 200 mg for 6
mo/
progression,
Ex þ Itra for 6
mo/ resolved
ND 29
34 51/ F Tac, MMF,
steroid
3 ND One
nodulopustule/
right knee
N N ND/ND A. alternata Ex þ Vori 400 mg
for 3
mo/ resolved
6 mo f/u:
no
lesion
30
amphB Z amphotericin B; AZA Z azathioprine; CsA Z cyclosporine; DC Z discontinue; DOD Z died of other disease; Ex Z excision; F Z female; Fluc Z fluconazole; FMS Z Fontana-
Masson stain; f/u Z follow-up; GMS Z Grocott’s methenamine silver stain; H&E Z hematoxylin and eosin; Hx Z history; Itra Z intraconazole; Keto Z ketoconazole; M Z male;
MMF Z mycophenolate mofetil; N Z no; ND Z no data; NI Z not identified to species level; PAS Z periodic acid-Schiff; Tac Z tacrolimus; Terb Z terbinafine; Vori Z voriconazole;
Y Z yes.
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Alternariosis in renal transplant recipient 57of immunosuppressants are recommended during and after
systemic antifungal therapy. Relapse may occur even after
prolonged treatment and long-term clinical follow-up
seems advisable.References
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